Cervical cancer - a single vaccine could benefit most womenSeptember 20, 2003The risk of developing cervical cancer by women infected with the Human Papillomavirus (HPV) is essentially the same no matter which type of virus is involved, provided it belongs to the group of 15 or so that are currently identified as high risk, a scientist said today. Speaking at ECCO 12 - The European Cancer Conference in Copenhagen, Dr. Xavier Bosch, of the Institut Catal' d'Oncologia, Barcelona, Spain, said that testing with a cocktail of the majority of high risk type virus would provide a sufficient answer for clinical guidance, and be important to the success of any future screening or vaccination programmes. HPV is an extremely common sexually transmitted infection. In many cases the infections are harmless and go away without the need for treatment.
But persistent infection with certain types of HPV increases the risk of cervical cancer. These types can be detected in 90-100% of cases of cervical cancer, as opposed to 5-20% of controls. These types are believed to be a necessary cause of cervical cancer and this provides a strong rationale for their use in screening and for the development of anti-HPV vaccines. "Women who are not infected persistently with one of the cancer-causing types of HPV do not develop cervical cancer", said Dr. Bosch, "and this knowledge is helping us develop effective prevention programmes." Dr. Bosch and colleagues derived their specific risk estimates from studying a pool of evidence collected by IARC, the International Agency for Research on Cancer, based in Lyon, France. In Europe it is estimated that 65000 new cases of cervical cancer are diagnosed each year, of which 21000 eventually lead to death. HPV carriers are typically young and sexually active, and evidence suggests that males and females are equally likely to be carriers. "In Europe and North America a vaccine including HPV 16 and 18 - the most common high risk types of the virus - would prevent 72% of cases among the vaccinated", said Dr. Bosch. "A vaccine containing types 16,18,33,31 and 45 would cover 84% of the cases." HPV vaccinations are still in the experimental stage, and the vaccine would be expensive at introduction, said Dr. Bosch. "But the gains in the longer term would be huge, both in terms of healthcare costs and in women's quality of life. In the meantime, participation in effective screening programs, particularly if they includes HPV testing, can detect and prevent many potential cases of cervical cancer at a very early stage." MR Communication and Analysis Ltd | |||||||||||||||||||||
|
Related Cervical Cancer Current Events and Cervical Cancer News Articles LSUHSC public health contributes to estimate of HPV-related cancers Professor Vivien Chen, PhD,. Associate Professor Xiao Cheng Wu, MD, PhD and Assistant Professor Edward Peters, DMD, SM, ScD, at LSU Health Sciences Center New Orleans School of Public Health contributed five papers to the largest most comprehensive assessment of the burden of human papillomavirus (HPV)-associated cancers in the United States to date. The health burden of raising a grandchild Precautionary health measures such as mammograms and cholesterol tests that identify the risk of heart disease are critical for the well-being of women over 50. Add the responsibility of providing sustained care for a grandchild, and these preventive examinations become even more important. Healthy bones program reduces hip fractures by 37 percent Proactive measures can reduce hip fracture rates by an average of 37.2 percent -- and as much as 50 percent -- among those at risk, according to a study conducted by Kaiser Permanente Southern California. The study was published online on November 3 by The Journal of Bone & Joint Surgery, a peer-reviewed journal. New MRI technique may identify cervical cancer early Using high-resolution magnetic resonance imaging (MRI) with a special vaginal coil, a technique to measure the movement of water within tissue, researchers may be able to identify cervical cancer in its early stages, according to a new study being published in the November issue of Radiology. Cancer screening rates among older Medicaid patients fall short of national objectives Only about half of Medicaid recipients age 50 and older appear to receive recommended screening tests for colorectal, breast and cervical cancer, according to a report in the October 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Social class dictates cancer risk Cervical and lung cancer are more common in poor people while rates of breast cancer and melanoma are higher in the wealthy. Model highlights benefits and risks of cervical cancer screening methods In an analysis based on a computer model, it appears that comparing the benefits and risks of different cervical cancer prevention approaches may help women and their physicians choose appropriate screening strategies. New HPV test for developing countries shows high accuracy in predicting cervical disease: Study A new HPV test developed by QIAGEN specifically for use in regions of the world with scarce resources is "substantially" more accurate in identifying women with cervical disease than the current methods (Pap testing and visual inspection) in these countries. As head and neck cancer risks evolve, more treatment options emerge Advances in understanding head and neck cancer over the last decade have led to more treatment options and improved quality of life for patients, according to a review published this week in the New England Journal of Medicine. Cervical cancer prevention should focus on vaccinating adolescent girls The cost-effectiveness of vaccination in the United States against human papillomavirus (HPV), a sexually-transmitted virus that causes cervical cancer, will be optimized by achieving universal vaccine coverage in young adolescent girls, by targeting initial "catch-up" efforts to vaccinate women younger than 21 years of age, and by revising current screening policies. More Cervical Cancer Current Events and Cervical Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||